On Demand Oral UPA + Meloxicam
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Pericoital
- Development Stage: Phase I
- Developer(s)/researcher(s): Stanford University
Details
- API: Ulipristal Acetate + Meloxicam
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Delay
- Regimen: On Demand
- MPT: Not Potential MPT
- Promising Attributes: Pericoital contraceptives may appeal to users interested in a hormonal method used only immediately before sexual contact, rather than continuously.
Product Status
Recent Clinical Development
History
Meloxicam has been evaluated in combination with both Levonorgestrel and UPA to improve efficacy of pericoital methods. Most recent development, including 2018-2019 Phase I trial, led by Stanford.
2022: Stanford publishes results of Phase I clinical evaluation, and indicates intention to pursue additional development.